Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 10 June 2027
- Last conf. stmt
- 27 May 2026
Oxford Biotherapeutics Ltd
- Incorporated
- 24 November 2003 (22 years)
- Previously known as
- Oxford Bio Therapeutics Ltd (until 16 March 2009)Oxford Genome Sciences (UK) Limited (until 26 November 2008)GW 1155 Limited (until 19 December 2003)
- Industry
- Research and experimental development on biotechnology (72110) Other research and experimental development on natural sciences and engineering (72190)Other professional, scientific and technical activities n.e.c. (74909)
- Directors
- Jean Pierre Bizzari
- Owned by
- Accounts type
- Group
- Region
- South East
- Address
- Suite ASecond FloorThe Schrodinger Building Heatley RoadOxford Science ParkOxfordOX4 4GE
Charges
- Total
- 5
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 5
Officers 4 active
Officer details are public data from the Companies House register.
Director · Appointed 15 December 2020
British
Born December 1969 (56)
Bizzari, Jean Pierre, Doctor
Director · Appointed 14 December 2016
French,American
Born October 1954 (72)
Director · Appointed 14 December 2016
German
Born December 1956 (69)
Director · Appointed 11 December 2003
German
Born March 1962 (64)
Officer history (22 former)
24 April 2023
Resigned Mchutchison, John George as Director
31 December 2020
15 December 2020
30 June 2020
Resigned Tomasello, Shawn Cline as Director
24 May 2017
Appointed Mchutchison, John George as Director
31 March 2017
Resigned Begley, Colin Glenn, Dr as Director
14 December 2016
14 December 2016
Appointed Bizzari, Jean Pierre, Doctor as Director
31 March 2016
31 March 2016
Resigned Rigby, Andrew Pryce as Secretary
31 March 2016
Resigned Reynolds, Thomas Curtis, Dr. as Director
29 September 2015
Appointed Tomasello, Shawn Cline as Director
29 September 2015
Resigned Pombo-Villar, Esteban, Dr as Director
20 January 2015
18 December 2014
Resigned Morton, Bryan Geoffrey as Director
21 July 2014
Appointed Rigby, Andrew Pryce as Secretary
12 June 2014
Resigned Livadiotis, Maria Juliet as Secretary
14 March 2014
Resigned Terrett, Jonathan Alexander as Director
15 January 2014
Appointed Reynolds, Thomas Curtis, Dr. as Director
15 January 2014
Resigned Hibberd, Christopher Richard as Director
12 September 2013
Resigned Rigby, Andrew Pryce as Secretary
12 September 2013
Appointed Livadiotis, Maria Juliet as Secretary
26 June 2013
Appointed Morton, Bryan Geoffrey as Director
26 June 2013
18 April 2013
Appointed Rigby, Andrew Pryce as Secretary
18 April 2013
Appointed Terrett, Jonathan Alexander as Director
18 April 2013
Resigned Lamble, Henry John, Dr as Secretary
2 May 2012
Appointed Pombo-Villar, Esteban, Dr as Director
9 January 2012
Appointed Begley, Colin Glenn, Dr as Director
14 April 2011
1 October 2009
27 November 2008
Resigned Barnes, Martin Paul, Dr as Director
14 November 2008
Appointed Lamble, Henry John, Dr as Secretary
30 October 2008
Resigned Barnes, Martin Paul, Dr as Secretary
18 October 2007
Appointed Hibberd, Christopher Richard as Director
30 May 2006
19 October 2005
Appointed Barnes, Martin Paul, Dr as Director
29 April 2005
Resigned Platt, Albert as Director
23 March 2005
23 March 2005
Appointed Barnes, Martin Paul, Dr as Secretary
23 March 2005
Resigned Zimmerman, Alexandra as Secretary
25 July 2004
Appointed Platt, Albert as Director
7 May 2004
Appointed Zimmerman, Alexandra as Secretary
7 May 2004
11 December 2003
11 December 2003
24 November 2003
24 November 2003
Ownership 3 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 24 November 2018
Owns 25–50% of shares
Corporate
Reg. no. 5929758
Corporate entity · Notified 24 November 2018
Owns 50–75% of shares
Corporate
Reg. no. 3963896
GKF Wealth Management Limited
Corporate entity · Notified 24 November 2018
Holds 25–50% of voting rights
Private Limited Company
Former controllers (1)
24 November 2018
Ceased Share Nominees Limited — Owns 25–50% of shares (as a trust)
Group structure 9 companies
Ownership group derived from the Companies House PSC register
West Midlands Enterprise Limited Owns 75–100% of shares
Lothian Fifty (890) Limited Owns 75–100% of shares
South East Growth Fund Managers Limited Owns 25–50% of shares
Oxford Biotherapeutics Ltd This company Owns 50–75% of shares
West Midlands Enterprise (Investments) Limited Owns 75–100% of shares
Wmeb Fund Managers Limited Owns 75–100% of shares
WM Enterprise Limited Owns 25–50% of shares
Wme Trustee Limited Owns 75–100% of shares
Financials
Figures from 2024 accounts. Newer accounts, made up to 31 December 2025, are filed but not read yet. See them on Companies House
- Net Assets
- £2,147,579
- Cash
- £4,622,357
- Profit
- £3,149,690
- Debt Ratio
- 78%
- Return on Equity
- 147%
Trend
Net Assets
Balance sheet detail
| 2024 | 2023 | |
|---|---|---|
| Fixed Assets | £273,332 | £314,434 |
| Current Assets | £9,580,753 | £15,811,411 |
| Debtors | £4,958,396 | £6,091,683 |
| Cash | £4,622,357 | £9,719,728 |
| Creditors (< 1 year) | £7,648,645 | |
| Creditors (> 1 year) | £1,317,648 | £9,626,835 |
| Net Current Assets | £3,191,895 | £8,162,766 |
| Net Assets | £2,147,579 | (£1,149,635) |
| Shareholder Funds | £2,147,579 | (£1,149,635) |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 9 June 2026 | Confirmation statement with updates | 27 May 2026 | ||
| 8 June 2026 | Change of details for a person with significant control | |||
| 29 October 2025 | Statement of capital following an allotment of shares | |||
| 5 September 2025 | Group of companies' accounts | 31 December 2024 | ||
| 9 June 2025 | Confirmation statement with updates | 27 May 2025 |
Other companies in this industry
Chalgrove
Runcorn
Altrincham
Manchester
Liverpool
Caerphilly
By trade and location
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →